LABP — Landos Biopharma Share Price
0.000.00%
Last trade - 00:00- $69.71m
- $40.70m
- 20
- 12
- 93
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.01 | ||
| Price to Tang. Book | 3.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.32% | ||
| Return on Equity | -70.67% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.
Directors
- Christopher Garabedian CHM (54)
- Timothy Mayleben PRE (61)
- Patricia Bitar CFO (59)
- Raquel Hontecillas CSO (49)
- Jyoti Chauhan EDR (32)
- Fred Callori DRC
- Tiago Girao DRC (41)
- Jean-Frederic Colombel IND (64)
- Roderick Wong IND (43)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 6th, 2017
- Public Since
- February 4th, 2021
- No. of Shareholders
- 8
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,125,841
- Address
- 1800 Kraft Drive, Suite 216, BLACKSBURG, 24060
- Web
- https://www.landosbiopharma.com/
- Phone
- +1 5408182844
- Auditors
- Ernst & Young LLP
Upcoming Events for LABP
Landos Biopharma Inc Annual Shareholders Meeting
Q2 2024 Landos Biopharma Inc Earnings Release
Q3 2024 Landos Biopharma Inc Earnings Release
Similar to LABP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Landos Biopharma share price?
As of Today at 16:29 UTC, shares in Landos Biopharma are trading at $22.30. This share price information is delayed by 15 minutes.
How has the Landos Biopharma share price performed this year?
Shares in Landos Biopharma last closed at $22.30 and the price had moved by +635.73% over the past 365 days. In terms of relative price strength the Landos Biopharma share price has outperformed the S&P500 Index by +473.16% over the past year.
What are the analyst and broker recommendations for Landos Biopharma?
The overall consensus recommendation for Landos Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Landos Biopharma dividend yield?
Landos Biopharma does not currently pay a dividend.
Does Landos Biopharma pay a dividend?
Landos Biopharma does not currently pay a dividend.
When does Landos Biopharma next pay dividends?
Landos Biopharma does not currently pay a dividend.
How do I buy Landos Biopharma shares?
To buy shares in Landos Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Landos Biopharma?
As of the previous close price of $22.30, shares in Landos Biopharma had a market capitalisation of $69.71m.
Where are Landos Biopharma shares listed?
Here are the trading details for Landos Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LABP
What kind of share is Landos Biopharma?
Based on an overall assessment of its quality, value and momentum Landos Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Landos Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Landos Biopharma is $12.71. That is 43% below the last closing price of $22.30.
Analysts covering Landos Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.19 for the next financial year.
What is the trend in the Landos Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Landos Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +332.27%.
As of the last closing price of $22.30, shares in Landos Biopharma were trading +176.59% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Landos Biopharma PE Ratio?
The Landos Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Landos Biopharma?
Landos Biopharma's management team is headed by:
- Christopher Garabedian - CHM
- Timothy Mayleben - PRE
- Patricia Bitar - CFO
- Raquel Hontecillas - CSO
- Jyoti Chauhan - EDR
- Fred Callori - DRC
- Tiago Girao - DRC
- Jean-Frederic Colombel - IND
- Roderick Wong - IND